For example, it has been shown that FoxO1 induces IGF1R, and this contributes to idelalisib resistance in TCL1-transgenic mice (72); however, we did not observe IGF1R induction during several weeks of idelalisib or ibrutinib therapy in CLL in vivo. This evidence concerns the gene FOXO1 and B-cell chronic lymphocytic leukemia.